Abbott Laboratories (ABT): Assessing the Path to the $150 Analyst Target
Key Takeaways
- The $150 central target is the arithmetic mean of roughly a dozen verified analyst price targets issued between late 2025 and early 2026, spanning an approximate range of $140 to $162.
- With the stock recently trading near $100.50, reaching $150 would require a gain of about 49%, a very large move relative to the current price.
- The strongest support for the target is Abbott's diversified healthcare portfolio and resilient medical-device franchise; the biggest risk is a recent guidance cut tied to weaker electrophysiology and diabetes momentum.
- Analyst views are broadly bullish but divided in magnitude, and several targets predate the company's most recent growth revision, so the mean may not fully reflect current conditions.
- For additional context, explore Abbott's Major News, Today's Price Move, Forecast, and Earnings pages.
- Readers can also explore Trending AI Robots to see AI-driven trading ideas across the market.
Analyst Price Targets and Consensus View
Abbott Laboratories (ABT) is a diversified global healthcare company spanning medical devices, diagnostics, nutrition, and established pharmaceuticals. Reviewing individual price targets attributed to specific firms and analysts, the range runs from about $140 (Mizuho's Neutral view) up to $162 (Barclays), with most targets clustered between roughly $142 and $154. Recent individual figures include RBC Capital at $147, Bernstein at $154 (raised from $150), Jefferies at $149, BTIG at $145, Wells Fargo at $146, Raymond James at $146, Piper Sandler at $150, and UBS at $154.
The arithmetic mean of these targets is roughly $148.6, which rounds to a $150 central target. This figure is an independently calculated average, not an official published consensus, and independent trackers have at times reported a slightly lower consensus of about $144 to $147. The broad agreement among analysts is an Outperform-to-Buy stance, with the divergence concentrated in magnitude: more cautious analysts cite diagnostics pricing pressure and uneven growth, while more bullish analysts emphasize medical-device momentum and long-term earnings power. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock recently traded near $100.50, well below its 52-week range of roughly $105 to $141 after a sustained 2026 decline. Reaching $150 from that level implies upside of approximately 49%, which is a very large required move. Notably, most of the analyst targets that anchor the $150 mean were set when the stock traded materially higher, so the gap between the current price and the average target partly reflects the share-price decline rather than a fresh round of upgrades.
Fundamentally, ABT has delivered mid-to-high single-digit revenue growth and maintains a diversified revenue base that includes high-demand categories such as glucose monitoring and structural heart devices. However, the company recently lowered its full-year comparable sales growth outlook, citing weakness in electrophysiology and diabetes. A path toward the target would likely require a stabilization and re-acceleration in those businesses, margin recovery, and renewed investor confidence in the valuation.
What Could Support a Move Toward the Target
Several factors could support a recovery. Abbott's medical-device segment, including its FreeStyle Libre continuous glucose monitoring platform and structural heart products, remains a durable growth engine with accelerating procedure volumes. The company's diversified model provides multiple revenue streams that can offset weakness in any single unit. A contemplated acquisition in the diagnostics and cancer-screening space is viewed by many analysts as strategically attractive over the long term, and Abbott's track record as an established dividend payer offers a measure of downside support. Analysts who remain constructive also point to a valuation that has compressed during the selloff and to double-digit earnings-growth potential if margins stabilize.
What Could Prevent the Target From Being Reached
The principal obstacle is the company's own guidance. The reduction in full-year comparable sales growth, driven by electrophysiology and diabetes, raises questions about near-term execution and the consistency of growth outside medical devices. Margin compression is another concern, as operating margins have slipped year over year. Integration risk and the premium valuation associated with a potential acquisition could also limit multiple expansion, while hospital budget pressures and reimbursement dynamics create macro uncertainty. Several price-target trims in recent quarters, even while ratings stayed positive, signal that investors may already be discounting a meaningful portion of the long-term growth story, leaving less room for error.
Technical Levels and Market Structure
After the 2026 decline, the stock sits near a multi-year support zone around the $100 area, with chart-based support observed near $95 and again near $89. On the upside, a notable resistance level appears around $128, where earlier rallies have stalled. That $128 area is itself well below the $150 central target, meaning the stock would first need to clear a series of intermediate resistance levels before approaching the analyst average. The long-term structure has weakened, with the stock below its prior highs and trading near the lower end of its recent range. From what I see, monitoring these levels closely helps frame the risk-reward setup.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts differ, and the targets referenced here were largely set before the most recent guidance revision. Investors should monitor upcoming earnings and guidance, particularly comparable sales growth in electrophysiology and diabetes, operating-margin trends, and any updates on the diagnostics acquisition. Analyst target revisions, hospital-procedure volume data, reimbursement decisions, and broader healthcare-sector sentiment will also matter. None of this provides a definitive forecast, but it frames the conditions under which the gap toward $150 could narrow or widen.
AI Daily Buy/Sell Signals
In my own analysis, I often turn to Tickeron's AI Daily Buy/Sell Signals to track momentum shifts in names like Abbott that have seen sharp reversals. The tool uses artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions and technical behavior. It helps spot evolving trends without manually reviewing every chart, which can be useful when evaluating whether conditions are aligning toward a higher price target or if near-term headwinds persist.
Final Assessment
The $150 target represents the arithmetic mean of verified analyst price targets, not a guarantee or a prediction. With the stock near $100.50, the move required is roughly 49%, which is very large, and the average target may not fully reflect the company's recent guidance cut and the sharp 2026 share-price decline. The strongest supports are Abbott's diversified portfolio and medical-device franchise, while the principal obstacles are weakening electrophysiology and diabetes momentum, margin pressure, and potential acquisition-related risk. Analyst disagreement centers on the magnitude of upside rather than direction. Investors should watch upcoming guidance, segment-level growth, and analyst revisions to gauge whether conditions are improving toward the target or drifting further away.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABT in +3.17% Uptrend, growing for three consecutive days on October 23, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABT advanced for three days, in 170 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Indicator exited the oversold zone, 19 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 51%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ABT as a result. In 43 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 25 of 54 cases over the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 54 cases where ABT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.511) is normal, around the industry mean (2.914). P/E Ratio (33.452) is within average values for comparable stocks, (1.904). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.052). Dividend Yield (0.024) settles around the average of (0.009) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care products
Industry MedicalNursingServices
Advertisement